Author name: Prestige

The veterinary laboratory achieved its profitability objectives over the last financial year but remains cautious for the next one. The animal health specialist experienced a spectacular recovery last year, as confirmed by the publication in January of organic revenue growth of 18.4%. A dynamic driven by the companion animals division and the United States, which

The strategic refocusing of the animal health specialist on its most promising niches is a success, as evidenced by the annual accounts. Vetoquinol had already revealed an annual turnover of 521 million euros, gross growth of 21.9% including 13.7% organic. The difference between the two progressions is mainly explained by the integration of Drontal and

A much better dynamic than expected at the start of the financial year The veterinary laboratory, despite a basis of comparison which has become high, published quarterly activity in very strong growth. On the stock market, the trend was less positive for Virbac shares since January 1, but the latest publication is now widely welcomed.

The veterinary laboratory is suffering from the downturn in the animal health market as evidenced by its quarterly activity, which was in organic decline. Investors finally welcomed the publication of Vetoquinol’s third quarter sales, with the stock increasing by almost 6% in the session that followed it. The market was clearly anticipating a more marked

The veterinary laboratory communicated its outlook for the next financial year, and the market expected better. The title of animal health specialist is at its lowest. Since the start of the year, it has seen almost half of its valuation disappear and it still loses almost 5% this morning after revealing its objectives for next

The veterinary laboratory published an annual turnover below expectations, due to a difficult time in Europe. The stock had benefited from the return to favor of growth stocks at the start of the year, but the publication of its fourth quarter sales brought it back to its level at the end of last year. The

The animal health specialist suffered in 2022, but the accounts and the new strategic plan were well received. Vetoquinol’s annual turnover was 5% below consensus expectations at 521 million euros, down 0.8% organically, slowed down by a third and final quarter with respective declines of 4.5 and 2.4%, causing the stock to fall. The publication

Virbac: the stock falls after a significant profit warning The veterinary laboratory finds itself in operational difficulty at the start of the financial year. He was also the victim of a cyberattack. The high basis of comparison made this first part of the year complicated for Virbac, after a good 2022 vintage. The first quarter

The veterinary laboratory reported half-yearly activity slightly better than anticipated. On the stock market, the title benefits. While the clouds were accumulating over the animal health specialist, and its stock was suffering, the publication of the half-yearly turnover gave the price some breathing room. Indeed, while Virbac revised its annual targets sharply downward at the